Favipiravir Experience in COVID-19 Patients at a Tertiary Center Intensive Care Unit
Acar Sevinc,
Favipiravir Experience in COVID-19 Patients at a Tertiary Center Intensive Care Unit,
, S., SiSli Etfal Hastanesi Tip Bulteni / The Medical Bulletin of Sisli Hospital, doi:10.14744/SEMB.2021.35902, NCT04645433
Retrospective 100 ICU patients in Turkey, showing improved survival with favipiravir vs. lopinavir/ritonavir.
This study is excluded in the after exclusion results of meta
analysis:
very late stage, ICU patients.
risk of death, 16.2% lower, RR 0.84, p = 0.38, treatment 57 of 85 (67.1%), control 12 of 15 (80.0%), NNT 7.7.
|
risk of mechanical ventilation, 10.3% lower, RR 0.90, p = 0.75, treatment 61 of 85 (71.8%), control 12 of 15 (80.0%), NNT 12.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Acar Sevinc et al., 28 Jun 2022, retrospective, Turkey, peer-reviewed, mean age 65.6, 1 author, study period 10 March, 2020 - 10 May, 2020, this trial compares with another treatment - results may be better when compared to placebo, trial
NCT04645433 (history).
Contact:
sultanacar34@hotmail.com.
Abstract: THE MEDICAL BULLETIN OF
SISLI ETFAL HOSPITAL
DOI: 10.14744/SEMB.2021.35902
Med Bull Sisli Etfal Hosp 2022;56(2):189–195
Original Research
Favipiravir Experience in COVID-19 Patients at a Tertiary
Center Intensive Care Unit
Sultan Acar Sevinc,1 Ayse Surhan Cinar,1 Nermin Balta Basi,1
Serkan Islamoglu,1 Mustafa Altinay,1 Haci Mustafa Ozdemir2
Seyhan Metin,1
Tugba Yucel,1
Department of Anesthesiology and Reanimation, University of Health Sciences Turkey, Sisli Hamidiye Etfal Training and Research
Hospital, Istanbul, Turkey
2
Department of Orthopedics, University of Health Sciences Turkey, Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey
1
Abstract
Objectives: The aim of this study was to compare intensive care unit (ICU) and overall hospital mortality in patients treated with
favipiravir and lopinavir-ritonavir for COVID-19.
Methods: Data were collected retrospectively between March 10 and May 10, 2020, from patients’ records admitted to ICU due to
COVID-19. Laboratory data, clinical characteristics, ICU and hospital mortality, ICU and hospital length of stay were compared in
patients treated with favipiravir and lopinavir-ritonavir.
Results: A total of 100 patients’ data were investigated. Favipiravir was used as the treatment for 85% of patients, with the rest
treated with lopinavir-ritonavir. Clinical and laboratory data of both antiviral treatment groups were similar. Length of hospital
stay was 16 (9–24) days with favipiravir and 8.5 (5–12.5) days with lopinavir-ritonavir (p=0.002). Length of ICU stay for favipiravir
and lopinavir-ritonavir groups were 8 (5–15) days and 4 (3–9) days, respectively (p=0.011). ICU mortality was 65.9% for the favipiravir and 80% for lopinavir-ritonavir (p=0.002). Hospital mortality for favipiravir and lopinavir-ritonavir was 67.1% and 80%,
respectively (p=0.001).
Conclusion: The mortality in patients treated with favipiravir was less than patients treated with lopinavir-ritonavir. Favipiravir
needs more attention and trials for its effect to be confirmed.
Keywords: COVID-19, intensive care unit, favipiravir, lopinavir-ritonavir, mortality
Please cite this article as ”Acar Sevinc S, Surhan Cinar A, Balta Basi N, Metin S, Yucel T, Islamoglu S, et al. Favipiravir Experience in COVID-19
Patients at a Tertiary Center Intensive Care Unit. Med Bull Sisli Etfal Hosp 2022;56(2):189–195”.
C
OVID-19 is the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
and may present in different clinical scenarios: About 80%
of patients present with mild, 13.8% present with severe
disease, and 6.1% with critical disease.[1] According to the
guidelines published by the Ministry of Health in Turkey,
patients with severe and critical disease were advised to be
admitted to intensive care unit (ICU).[2] Turkey diagnosed
Address for correspondence: Sultan Acar Sevinc, MD. Sisli Hamidiye Etfal Egitim ve Arastirma Hastanesi, Anesteziyoloji ve
Reanimasyon Bolumu, Istanbul, Turkey
Phone: +90 212 373 50 00 E-mail: sultanacar34@hotmail.com
Submitted Date: July 13, 2021 Accepted Date: September 18, 2021 Available Online Date: June 28, 2022
©
Copyright 2022 by The Medical Bulletin of Sisli Etfal Hospital - Available online at www.sislietfaltip.org
OPEN ACCESS This is an open access article under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/).
190
its first COVID-19 case on March 11, 2020. A detailed treatment algorithm was published on April 14,..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit